Proposed changes to how the military acquires and tests weapons expose taxpayers to more wasteful spending while undermining ...
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...
Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca's IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈